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PREVALENCE, ETIOLOGY, AND TREATMENT OF SLEEP DISORDERS IN  
 
AUTISM SPECTRUM DISORDER  
BRYANT DUY CHANG 
ABSTRACT 
Background: Autism Spectrum Disorder is a range of neurodevelopmental disorders that 
typical manifest as social deficits, delayed or impaired communication skills, and 
repetitive behaviors in day-to-day life. Patients with Autism Spectrum Disorder (ASD) 
often present with other concurrent clinical disorders. Sleep disorders (SD) and sleep 
issues are highly prevalent in ASD children and rank as one of the most common 
concurrent clinical disorders. Prevalence rates vary widely, ranging from 40 to 80 
percent, as compared with that of typically developing children in which prevalence rates 
are approximately 30 percent. Sleep problems can have an impact on daytime health and 
may result in neurocognitive dysfunction and behavioral disruptions. A cyclical pattern 
arises: individuals with autism are observed to have sleep difficulties, which may 
exacerbate autistic traits, which can in turn further worsen their quality of sleep. 
Therefore, sleep disorders may have wide ranging effects on daytime functioning, 
developmental progress, and quality of life for children with ASD.  
 
Objectives: The purpose of this thesis is to provide a review of the research status of 
ASD, SD, the interplay between these two disorders, and therapeutic interventions that 
have been researched or are currently being investigated. A goal of this thesis is also to 
recommend areas of future investigation based on the current state of autism research. 
 
 vi 
Methods: A literature review of studies, abstracts, and clinical trial data relating to ASD, 
SD, and other comorbidities observed in ASD was performed.  
 
Conclusion: Current models and theories on the relationship between ASD and SD 
suggest that the underlying etiology of autism itself may contribute to sleep troubles, and 
might even have wide-reaching impacts on other unrelated aspects of ASD. 
Gastrointestinal, otolaryngologic, and psychiatric comorbidities are observed in autism 
and may affect sleep in these patients, but the mechanism by which this occurs is unclear. 
There are many treatments for sleep troubles in ASD such as melatonin and behavioral 
interventions, with varying success. Much work is required to understand the underlying 
mechanism between both autism and sleep disorders. There is also a need for more 
efficacious therapeutic interventions, but there are multiple clinical trials underway which 
may have promising results. Future studies should also incorporate robust data-collection 
instruments such as polysomnography to validate findings.   
 
 vii 
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Autism spectrum disorder (ASD) as it is defined in the Diagnostic and Statistical 
Manual of Mental Disorders, Fifth Edition (DSM-5) is a range of neurodevelopmental 
disorders that includes but is not limited to autism and related conditions. The most 
common characteristics of a person with autism are social deficits, delayed or impaired 
communication skills, and repetitive behaviors in day-to-day life.11 It is important to 
remember however that autism and its related conditions are highly variable in their 
presentation, and is it still unclear whether this heterogeneity in both presentation and 
symptom severity are due to shared underlying causes. 10 Furthermore, there is still no 
concrete evidence that points toward a neurobiological process that causes a child to be 
born with autism.8, 11 A variety of genetic and environmental factors have been shown to 
potentially increase the risk of autism.42 Yet, the exact differences between an autistic 
and normal brain are still not fully understood.5 Symptoms of autism result from complex 
changes in multiple systems of the brain. The mechanism by which autism manifests 
itself may be broken down into two areas: the changes in brain structures that lead to 
different brain processes related to autism, and the changes in brain structures that lead to 
pathological changes in behavior. Current research suggests that the behaviors are likely 
due to a combination of multiple pathophysiologies.5, 8, 42 
The underlying mechanism of ASD is not fully understood at either the 
molecular, cellular, or systems level.5 Research suggests that the predominant causes of 
 
2 
autism are genetic factors, but the understanding of other aspects such as heritability and 
epigenetic factors remains incomplete.42 The constellation of traits shared by children 
with autism: a lack of social awareness, rigidity of behavior, and irregularities of speech 
are just three of the multiple comorbidities that also affect children on the spectrum.62  
Many present with sleep disorders as well as gastrointestinal and otolaryngologic 
symptoms.62 The aim of this thesis is to outline the relationship between autism and sleep 
disorders in children. 
 
Specific Aims 
The purpose of this thesis is to review the clinical and research status of the 
autism spectrum disorders, sleep disorders, and potential relationships between the two 
disorders. A cumulative analysis of pertinent literature and current therapeutic 
interventions will be described, as well as ongoing clinical trial information will be 
discussed, and future research directions suggested. 
 
History of autism research 
There are two figures who have formed the basis of autism research: Leo Kanner 
and Hans Asperger. Leo Kanner was an Austrian-American psychiatrist best known for 
describing “Early Infantile Autism”, which today is simply referred to as autism. In 1943, 
Kanner published a case series entitled: "Autistic Disturbances of Affective Contact," in 
which he described 11 of his pediatric patients who were highly intelligent and 
precocious, yet all shared an “intense desire for aloneness" and "an obsessive insistence 
 
3 
on persistent sameness.”1 It was from this landmark paper that autism research sprung 
forth in the United States, and Kanner’s publication would go on to be one of the most 
frequently cited papers in autism research. Similarly, another Austrian pediatrician, Hans 
Asperger, published several papers, most of which discussed a disorder he had coined: 
autistic psychopathy. In 1944, Asperger described the cases of four boys that displayed 
unique abilities and patterns of behavior that were characterized by intense absorption in 
a special interest, lack of empathy, inability to form friendships, physical clumsiness, and 
one-sided conversations.2 Asperger’s work received recognition and notoriety only after 
1981, when his work was translated into English and re-introduced to the scientific 
community. It was at this point that child psychiatrist, Dr. Lorna Wing reintroduced 
Asperger’s work to the English-speaking medical community and popularized the term: 
“Asperger's syndrome”, named after the Austrian pediatrician himself. 11 
Kanner and Asperger were unaware of each other’s work when they published 
their respective observations: they were separated by an ocean and a world war. In 
contrast to Kanner’s immediate recognition for describing a new medical condition, 
Asperger's descriptions went unnoticed in the United States, likely due to the fact that 
Asperger published his work in German. Kanner and Asperger described two different 
subtypes of autism. Kanner described what is generally considered to be “classical-
autism”, characterized by significant cognitive and communicative deficiencies, and 
delayed or absent language development.1 Asperger on the other hand delineated the 
cases of 4 young boys where speech was less commonly absent or delayed, motor deficits 
were common, the onset of symptoms appeared and were recognized later in 
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development.2 Furthermore, Asperger noticed that many of the children he had identified 
as being autistic managed to overcome their disabilities and transitioned into meaningful 
and fulfilling careers as adults.2 
Starting in the 1980s and 90s, parents began to self-organize and formed 
communities where they could share information related to autism and raising children 
with autism. These would later evolve into international organizations that focused on 
autism. The goal of these organizations was not uniform as some organizations aimed to 
seek a “cure” for autism, while others sought to raise awareness and change society in a 
way that would be more accepting of the disorder. One such organization was the Autism 
Research Institute (ARI), founded by Bernard Rimland, a relative outsider to the field. 
Rimland was a psychologist who had a son with autism, but dove into the literature to 
find a cure for his son’s condition. In 1967, with the support of other families having 
children on the spectrum, he founded ARI. Many other organizations such as the Autism 
Society of America (ASA) and Autism Speaks were later founded by parents who found 
a benefit in sharing their experiences with other parents of children with the same 
disorder. Today these organizations represent the major share of advocacy and research 
organizations for autism in the United States. 
The history of autism research has been controversial and tumultuous, owing to 
fierce debates that are still being argued today. One of the more current examples of such 
controversy centers around the now recognized fraudulent research paper authored by 
Andrew Wakefield and published in 1998, in which the measles, mumps and rubella 
(MMR) vaccine was stated to be a cause of autism. Although the paper has since been 
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discredited and any linkage between the MMR and ASD scientifically disproven, several 
figures in autism including Rimland were proponents of this theory. Rimland was also 
notable for purporting that a regimen of vitamin B6 and magnesium could bring about 
behavioral changes and cure autism - an idea which lacks strong empirical evidence 
today. More recently, families of children with autism have described improvement in 
their children if fed a gluten-free diet. Current literature suggests however that there is 
little to no benefit of such a diet, and that whatever benefits of such a diet may occur 
remain anecdotal.3  
Autism and its related disorders are typically diagnosed by healthcare providers 
with the help of specific validated clinical and diagnostic measures. Two such 
instruments are the Autism Diagnostic Observation Schedule (ADOS) and the Autism 
Diagnostic Interview-Revised (ADI-R). The ADOS and ADI-R are standardized and 
validated measures for clinical and research use and are considered the gold standard 
tests for diagnosis of ASD. The ADOS and ADI-R were both developed by Drs. Lord, 
Rutter, DiLavore, and Risi in 1989.4, 5 The ADOS protocol is a 45 minute instrument 
which consists of a number of both structured and semi-structured tasks involving social 
interaction between the examiner and subject. Observations of a subject’s behavior are 
categorized into predetermined categories, and these observations are combined to 
produce quantitative scores for further analysis. The ADI-R is a 90 minute structured 
interview conducted with parents of children referred for evaluation of autism, and 
involves discussing the entirety of the child’s developmental history.  
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Another tool used in the diagnosis of ASD is the Diagnostic and Statistical 
Manual of Mental Disorders (DSM) published by the American Psychiatric Association. 
In the United States the DSM serves as the authoritative source for making psychiatric 
diagnoses. In the fourth iteration of the DSM, the DSM-4, Autism disorder and Asperger 
syndrome were separate diagnoses with corresponding diagnostic criteria. Following the 
release of the DSM-5 in 2013, Autistic disorder, Asperger syndrome, and two other 
related disorders: Childhood disintegrative disorder and Pervasive Developmental 
Disorder-Not Otherwise Specified (PDD-NOS) were consolidated into one umbrella 
diagnosis of Autism Spectrum Disorder (ASD). The DSM-4 outlined three categories of 
autism symptoms: 1) Social impairment, 2) Language/communication impairment, and 3) 
Repetitive/restricted behaviors. The DSM-5 consolidated these categories into two 
categories of symptoms: 1) Persistent deficits in social communication/interaction and 2) 
Restricted, repetitive patterns of behavior. Today, research interest is strong and 
continues to grow, and seeks to understand the complex etiologies of autism and to 
recognize the concomitant medical, neurological, and psychiatric conditions that may 
impact or influence symptoms and clinical presentation. 
 
Clinical features of Autism 
ASD is a neurodevelopmental disability that often manifests as a collection of 
symptoms and that can be associated with significant emotional, social, and behavioral 
dysfunction. ASD, as the name implies, is currently defined as a spectrum of disorders 
that range in both symptoms and severity. This range leads to a distinction between 
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severely disabled people with autism who are unable speak or take care of themselves, to 
individuals with “higher-functioning” autism, who are able to look after themselves but 
may exhibit social skills deficits and communication problems. 
Individuals with autism also tend to display either hypersensitivity and/or 
hyposensitivity to external sensory information.11,13 Examples of hypersensitivity include 
increased touch and/or sound sensitivity, termed tactile hyperesthesia and auditory 
hyperesthesia respectively, increased light sensitivity or photophobia, and increased 
sensitivity to smells, also known as hyperosmia. These increased sensitivities may 
present difficult challenges to individuals on the spectrum, who may find every-day 
stimuli to be unpleasant, overwhelming, and in some cases painful. On the other hand, 
individuals with ASD may exhibit hyposensitivities such as a diminished sense of touch. 
Such individuals may in turn seek tactile sensory stimulation which can take the form of 
biting and/or hugging themselves, chewing/sucking on objects, and banging their head 
against walls. It has also been reported that children on the spectrum enjoy deep pressure 
while under weighted blankets.6  
Atypical social development in people with autism is typically defined by lack of 
intuition and failure to understand/process social communication. This unusual social 
pattern is often first observed in early childhood. 62 Infants with autism exhibit less 
attention to social stimuli, show decreased or no reciprocation to social cues, and respond 
less to their own name. Toddlers with autism also differ in adherence to social norms - 
they may make less eye contact and their social interactions can be significantly limited, 
including the inability to participate in turn-taking.7,62 Children and adolescents with 
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high-functioning autism frequently suffer from feelings of loneliness and isolation 
compared to typically developing (TD) children.7 Anecdotal reports and a handful of 
systematic reviews indicate that autism can, in some cases, be associated with aggression, 
violence, and meltdowns.8  
Atypical communication skills are observed in roughly a third of people with 
autism.9 Delayed onset of babbling, diminished responsiveness to caregivers as well as 
strangers, and the repetition of words heard from caregivers or strangers, termed 
echolalia, are all typical characteristics of communication dysfunction in children on the 
spectrum.  
Behaviorally, children with ASD show a collection of atypical behaviors and 
habits. Repetitive behaviors, often referred to as “stimming”, and other stereotyped 
behaviors such as hand flapping, repetitive head movements, and marching in place may 
be manifest.11 The relation of these behaviors to hyper- or hyposensitivities is not well 
understood. Compulsive habits that are often time-consuming but intended to reduce 
anxiety are also noted. These habits are typically bounded by strict and rigid rules, such 
as ensuring objects are placed in specific arrangements and locations, unchanged dressing 
routines, and excessive hand washing. In severe cases, there may also be self-injurious 
behavior, such as skin-picking, hand biting, and head-banging. Finally, restricted 
interests, fixations, and preferences are often observed, such as preoccupation with a 
game or television show, or specific food choices.10  
Patients with ASD may manifest other comorbidities, such as gastrointestinal, 
neurological, and/or sleep disorders.11 Whether these concomitant disorders arise from a 
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causal relationship in ASD is not fully understood. Additional comorbidities may include 
anxiety, depression, attention-deficit hyperactivity disorder (ADHD), epilepsy, 
schizophrenia, and sleep apnea.62  
Some children with autism may also experience regression. In one review article, 
it is reported that roughly one-third of young children on the spectrum regress during 
early development.13 Regression generally results in loss of speech, but also may affect 
non-verbal communication and other social skills. However, normal development of 
speech and social skills followed by regression does not predict future developmental 
outcomes.12, 13 The underlying mechanisms leading to regression in autism are still 
unknown, but there is evidence that suggests children who regress exhibit subtle 
differences in sleep patterns as compared to their peers with autism that do not regress. 
Such differences include sleep troubles such as less time spent asleep and longer onset to 
sleep, but further work needs to be done to illuminate any causal relationships. Further 
complicating these observations is the role of sub-clinical epilepsy and epilepsy, which 
has been weakly associated with regression, but the validity and impact of which remains 
unclear.13, 14  
 
Treatment of Autism 
There is no known cure for autism. However, patients with Asperger syndrome 
and those with high-functioning autism are able to care for themselves as adults and may 
even experience decreased symptom severity over the course of a lifetime.15 The 
overarching goals of therapy are to decrease social, behavioral, communicative, and 
 
10 
emotional deficits, increase quality of life, enable functional independence, and lessen 
family distress. Therapeutic interventions in autism may be broadly divided into three 
categories: clinical, behavioral, and pharmacologic. 
 
Clinical treatments 
Clinical treatment of autism involves managing medical comorbidities that are 
often observed in children with ASD. These include but are not limited to gastrointestinal 
(GI) issues, otolaryngologic (ENT) problems, and psychiatric conditions. Management of 
these comorbidities does not differ radically in ASD children compared to TD children, 
but nonetheless presents challenges to parents and healthcare providers.  
Children on the spectrum are at higher risk of having chronic constipation, 
diarrhea, and abdominal pains and may present with behavioral manifestations.62,91  
Underlying mechanisms of these GI issues and whether the underlying etiologies are 
unique to ASD is unclear. However, it has been suggested that pathways in the gut-brain 
axis may play a role in altering behavior and cognitive skills.16, 17 Other factors that may 
be potential links between ASD and GI disorders are autoimmune-triggered intestinal 
inflammation, gluten metabolism disorders such as celiac disease and wheat allergies, 
and immunoglobulin E-mediated or cell-mediated GI disturbances. These aspects of GI 
issues are suggested to have an impact on brain development and neurochemistry, but 
further work is needed to elucidate the specific mechanisms of pathophysiology.17 There 
are currently no evidence-based treatment recommendations to address GI issues in 
patients on the spectrum, but general consensus indicates that ASD individuals should 
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receive the same standard of care in diagnosis and treatment of GI concerns.18 However, 
caregivers should also be aware that treatment of these conditions may be especially 
challenging in non-verbal patients who are find it difficult or are unable to express what 
is bothering them. Additionally, it has been suggested that a combination of behavioral 
and medical treatment may be more beneficial.18 Gluten-free diets to treat autism have 
also been suggested by parents of children with ASD and some clinicians.19 Some 
parental reports describe improvement in autistic behaviors after their children were 
started on a gluten-free diet.19 Indeed, a recent review indicates that a phenotypic 
subgroup of patients might benefit from a gluten-free diet.3,19 However, this same review 
concludes that there is insufficient data to support the use of a gluten-free diet for all 
individuals on the spectrum, and that more work is required to elucidate the relationship 
between autism and GI disorders.3,19 
Otolaryngologic conditions observed in ASD include sleep apnea, enlarged 
adenoids, and sinusitis.11 Management of these conditions also does not significantly 
differ from TD peers.20, 21 However, treatment of these conditions has been correlated 
with improvement in autistic symptoms. Surgical intervention for obstructive sleep apnea 
(OSA), adenotonsillectomy (AT) in children with ASD demonstrated improvements in 
autistic symptoms.21 Further work describing mechanisms of effect of these ENT 




Behavioral interventions such as Applied Behavioral Analysis (ABA), 
Developmental Social-Pragmatic Model (DSP), and Cognitive Behavioral Therapy 
(CBT) are frequently used. 24  These methods are techniques rooted in spending time with 
children and engaging in exercises which aim to change autistic behavior. ABA 
practitioners focus on rewarding positive behavior, such as sitting quietly, reading a 
book, and engaging in physical contact, while extinguishing negative behavior such as 
loud outbursts, erratic movements, and repetitive motions. DSP aims to build and 
enhance a patient’s communication skills by simulating natural and/or unusual scenarios 
where focus is placed on spontaneous initiation of communication or interaction. DSP is 
used to aid children in forming meaningful and positive relationships with peers and 
caregivers that would otherwise be difficult or impossible without treatment. In practice, 
ABA may be employed separately or in conjunction with DSP.22 CBT differs in nature by 
focusing on changing attitudes, thoughts, beliefs, and how they relate to how a person 
deals with emotional problems. CBT modifies a person’s cognitive processes, whereas 
ABA and DSP modifies a person’s behavior. There is sparse literature which describes 
the usage rates of ABA/DSP, but its efficacy is more established. The American 
Academy of Pediatrics prescribes ABA as the primary treatment for autism, and 
numerous reviews of ABA efficacy show improvements in cognitive performance, 
communication skills, and social skills.23, 24 However, ABA effectiveness can be limited 
with increased autism severity and lower efficacy has been associated with lower 
intelligence quotient.25 Further, some groups such as the Autistic Self Advocacy Network 
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state that potential negative outcomes/practices in ABA such as verbal abuse and restraint 
are sufficient to argue against its use.26 
 
Pharmacological treatments 
Similar to behavioral interventions, pharmacological treatment of ASD involves 
improving symptoms of ASD, rather than treating underlying causes. However, as of the 
time of writing, there are no medications proven to be efficacious in treating the core 
symptoms of ASD.27 Antipsychotics, anticonvulsants, antidepressants, and stimulants are 
the most commonly reported classes of medications used to target emotional and 
behavioral symptoms of ASD. More than half of children in the United States diagnosed 
with ASD are prescribed psychoactive drugs or anticonvulsants, and psychotropic 
polypharmacy is also a common feature.28, 29 Currently, only two medications: 
risperidone and aripiprazole are approved by the Food and Drug Administration (FDA) to 
treat irritability in children with ASD. Other medications are also prescribed “off-label”, 
meaning they have not been approved by the FDA to treat autism. However, certain 
studies evaluating efficacy, safety, and adverse effects of these medications conclude that 
some drug classes such as selective serotonin reuptake inhibitors (SSRI) antidepressants 
lacked sufficient evidence and efficacy to recommend prescription to treat autism.30 
Emergent research indicate that gamma-aminobutyric acid (GABA) modulating agents, 
oxytocin supplementation, cannabidiol oil, and nutritional supplements coupled with 
dietary modification may have therapeutic potential.31 Additionally, methylphenidate and 
atomoxetine were shown to be effective in improving symptoms of hyperactivity and 
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inattention in children who had ASD, but notably may cause some side effects including 
decreased sleep and appetite.27,32 30 Further, transdermal nicotine was demonstrated to be 
effective in reducing symptoms of aggression in ASD.33 Other medications being 
investigated include buspirone for treatment of repetitive behaviors. GABAergic and 
cholinergic agents as well as oxytocin show inconsistent results, and SSRIs are generally 
poorly tolerated with lack of substantial evidence in decreasing repetitive behaviors.27 
Finally, significant improvement in language development and social behavior has been 
demonstrated with memantine. Further research related to its effect in adults with ASD 




In typically developing individuals, sleep has a myriad of important functions 
necessary for survival and maintenance of daily activities. During sleep, humans 
physically restore themselves, undergoing healing and restorative processes such as 
removing metabolic waste products that build up during waking hours. 38 Besides 
homeostatic functions, sleep is also essential for learning, memory consolidation, and for 
encoding information for storage and later recall. Key areas of the brain involved in sleep 
are the hypothalamus - specifically the suprachiasmatic nucleus (SCN) located within the 
hypothalamus, as well as the brain stem, thalamus, basal forebrain (BF), and the 
amygdala.37,38  In concert, these brain areas act to maintain wakefulness, promote sleep, 
and regulate sleep architecture. As the day progresses and humans remain in a state of 
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wakefulness, compounds such as adenosine, the by-product of cellular metabolism, and 
nitric oxide gas accumulate in the BF and the cerebral cortex.38 Adenosine and nitric 
oxide (NO) act at their respective receptors within the BF to promote sleepiness and 
impair alertness.37 These neurochemical changes are indicative of time spent awake, as in 
the case of adenosine, where endogenous, extracellular adenosine in the BF increases 
with longer periods of wakefulness.36 Other chemical compounds important for sleep are 
the neurotransmitters which modulate activity of cells in the brain that control arousal or 
relaxation. Gamma-aminobutyric acid (GABA) is an inhibitory neurotransmitter that is 
implicated in not just sleep, but also muscle relaxation and general sedation. 
Norepinephrine and orexin on the other hand function to promote wakefulness and 
vigilance. Other neurotransmitters that have been characterized in sleep are serotonin, 
cortisol, acetylcholine, histamine, and adrenaline.37  
 
Sleep Architecture 
Sleep architecture refers to the cyclical pattern of different sleep stages that 
humans enter and exit during sleep. Sleep can broadly be divided into two types: 1) non-
rapid eye movement (NREM) sleep, which normally precedes 2) rapid eye movement 
(REM) sleep. In a typical night of sleep, humans complete 3-4 cycles of NREM and 
REM sleep, although adolescents typically go through a higher number of stages.37 
Within NREM sleep, there are three distinct stages of sleep: stage 1, stage 2, and stage 3. 
Stage 1 sleep is often termed pre-sleep and is the transitional stage between wakefulness 
and sleep characterized by decreased heart rate, respiratory rate, and muscle relaxation. 38 
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Stage 2 sleep is the stage in which the most time is spent during a normal night’s sleep, 
and is the first stage during which body temperature decreases and eye movements stop. 
It is also characterized by continued slowing of brain wave activity.38 Stage 3, which is 
also referred to as slow-wave sleep or deep sleep, is the stage during which learning, 
memory consolidation, and the restorative processes discussed earlier occur. This stage 
features the lowest heart rate and breathing rate, as well as further muscle relaxation. 38 
Deep sleep is the most difficult stage to awaken from, and also exhibits the highest 
thresholds for waking.37 REM sleep on the other hand is markedly different from all 
stages of non-REM sleep and is characterized by random/rapid movement of the eyes, 
irregular breathing patterns, and increased heart rate and blood pressure that are close to 
waking levels. Most notably however is temporary paralysis of the extremities. This is 
related to the fact that REM sleep is the stage during which dreaming is thought to occur, 
and has also been implicated in learning and creativity.36, 38 Paralysis of skeletal muscle 
serves to protect the body from acting out or acting upon dreams experienced during 
REM sleep.36 
 The different sleep stages are demarcated from each other by a set of 
neurological, physiological, and EEG characteristics. These characteristics are often 
studied through polysomnography (PSG), which collectively records several body 
functions through electrophysiology, and which is the measurement of neuronal or organ-
level changes in voltage or current. Brain, eye, muscle and heart activity are measured via 
electroencephalography (EEG), electrooculography (EOG), electromyography (EMG), 
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and electrocardiography (EKG), respectively. PSG also measures pulmonary function 
through respiratory air flow and respiratory effort. 
Neurologically, the progression into deeper NREM stages can be thought of as 
falling into deeper sleep - sensorimotor processing is the most impaired in stage 3 sleep, 
resulting in the highest thresholds for waking compared to stages 1 and 2. Neuronal 
activity progressively declines when entering deeper stages of NREM sleep, which 
reflects the decreased brain activity observed in slow-wave sleep.38 Stage 3 is also the 
stage during which sleep disorders are typically manifest, such as sleep walking, night 
terrors, and bed wetting.36,38 The characteristic atonia observed in REM sleep also 
increases the likelihood of temporary airway collapse, leading to obstructive sleep apnea 
(OSA), although it should be noted OSA may occur during all stages of sleep.37  
Physiologically, brain activity gradually decreases as sleep progresses into its 
deeper stages. Within the hypothalamus is the suprachiasmatic nucleus (SCN), which is 
made of several clusters of neurons that receive and process information regarding light 
exposure from the eyes.38 SCN activity then either upregulates or downregulates 
sleepiness in accordance with light exposure to the eyes. SCN activity is lower in NREM 
sleep when compared to REM sleep.38 The brain stem, made of structures including the 
pons, medulla, and midbrain, also plays a significant role in sleep onset during REM 
sleep. Sleep-promoting cells within both the brainstem and hypothalamus produce 
GABA, which promotes sleep. Additionally, the pons and medulla are associated with 
REM sleep, whereby these areas send inhibitory signals to skeletal muscle that control 
limb movement and body posture.36As discussed previously, the function of skeletal 
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muscle paralysis is to prevent dreams occurring during REM sleep from becoming 
physically manifest, a situation known as REM sleep behavior disorder.37,38 The thalamus 
acts as a relay center for information heading towards the cerebral cortex. In NREM 
sleep, activity of the thalamus gradually decreases, so that incoming sensory information 
does not disturb sleep.39 During REM sleep however, activity of the thalamus increases, 
and functions to send the cerebral cortex sensory information that may affect dreams.39 
Another brain area that displays physiological differences during NREM and REM is the 
amygdala, which normally serves to process emotions. During REM sleep, the activity 
within the amygdala increases, and functions to aid memory and emotional processing 
that occurs during dreaming.40  
Brain activity measured through EEG has been able to define discrete differences 
that are characteristics of each sleep stage. In NREM sleep, stages 1 and 2 are 
characterized by decreased brain activity that results in decreased electrical activity.39 
The distinct EEG waveforms of stage 2 sleep include K complexes, as well as sleep 
spindles.39 Stage 3 sleep has been referred to as delta sleep, owing to the presence of delta 
waveforms on the EEG. REM sleep, as the name suggests, exhibits disordered EEG 
waveforms, such as theta and beta waves.39,40 
 
Sleep regulation 
Two internal biological mechanisms regulate sleep and wake states in humans - 
circadian rhythm and sleep-wake homeostasis. Circadian rhythms are responsible for not 
only daily fluctuations in wakefulness, but also changes in body temperature, 
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metabolism, and hormone release.40 Sleep-wake homeostasis on the other hand, refers to 
the natural tendency that drives the body to sleep after a certain time spent awake. Factors 
that influence this sleep drive may include medical conditions, daily stressors, food 
intake, and sleep environment.40 Sleep homeostasis also mirrors the build-up sleep 
homeostatic factors, such as adenosine and NO, both of which increase the physiological 
drive to enter NREM sleep.37, 40 One factor that influences both circadian rhythm as well 
as sleep drive is light exposure - either from natural light or artificial light. The SCN 
processes information relating to light exposure and is responsible for coordination 
between environmental light-dark cycles and sleep homeostasis. The SCN also maintains 
circadian rhythms via the synchronization of environmental and endogenous cues.41  
Sleep onset may be modeled as turning on certain sleep-promoting areas in the 
brain, and turning off other areas that maintain wakefulness. The awake state is 
maintained by neurons originating in the lateral hypothalamus (LH) and inhibitory input 
towards an area found in the anterior hypothalamus, the ventrolateral preoptic nucleus 
(VLPO).40, 41 During sleep, GABAergic neurons from the VPLO inhibit wake-promoting 
nuclei such as the LH. Thus, the gradual transition between wake and sleep is due to the 
mutual inhibition of these and other sleep- and wake-controlling nuclei. Circadian rhythm 
and sleep drive are involved in the control of this reciprocal mechanism via upstream 
regulation of the GABAergic neurons and originates from the SCN.37 This “flip-flop” 





Figure 1: “Flip-flop” model of transition from wakefulness to sleep. This model 
illustrates the mutual inhibition and activation of sleep- and wake-promoting nuclei that 
initiate and maintain sleep/wake states. The lateral hypothalamic (LH) maintains the 
wake state via GABAergic and histaminergic neurons of the tuberomammillary nucleus 
(TMN), serotonergic neurons of the dorsal raphe nucleus (DR), and noradrenergic 
neurons of the locus coeruleus (LC). The ventrolateral preoptic (VLPO) neurons maintain 
the sleep state via GABAergic and galaninergic nuclei that project to the LH. Taken from 
(Brown et. al., 2012) 
 
Control of sleep also has a significant genetic component. Several genes are 
implicated in sleep and sleep disorders, such as genes that regulate neuronal excitability, 
and “clock” genes, such as PER, TIM, CLOCK, and CRY, that influence circadian 
rhythms and sleep timing.16, 17 Certain clock genes, such as PER1 and NPAS2 have been 
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associated in the etiology of autism. Additionally, several sleep problems such as reduced 
NREM sleep, prolonged waking after sleep onset, and longer sleep latency are 
attributable to mutations in these genes as well.17, 42  
Sleep disorders 
 Sleep disorders (SD) may be broadly divided into four categories: dyssomnias 
parasomnias, circadian rhythm sleep disorders, disorders that originate from a medical or 
psychological condition, and sleeping sickness. Insomnia is specifically defined as 
difficulty falling asleep and/or maintaining sleep without an obvious identifiable cause or 
precipitating factors. Dyssomnias are characterized by hypersomnia - excessive sleeping 
or sleepiness, or insomnia. This category of SD includes disorders that are related to 
respiratory function, such as disordered breathing patterns, snoring, and sleep apnea. 
Sleep apnea is a sleep disorder where patients exhibit shallow breathing or experience 
pauses in breathing during sleep. Sleep apnea is further divided into three forms: 
obstructive sleep apnea (OSA), central sleep apnea (CSA), and a combination the two 
termed mixed sleep apnea. OSA is the result of the complete or partial obstruction of the 
upper airway, while CSA is due to alterations in the neurologic regulation of breathing. 
Parasomnias are the class of sleep disorder that involves abnormal movements, 
behaviors, emotions, and dreams in relation to sleep. Such disorders include bedwetting, 
sleep terrors, sleepwalking, and sleep talking. Medical or psychiatric conditions that may 
produce sleep disorders secondary to the primary disease are mood disorders, anxiety 
disorders, depression, and schizophrenia. Finally, sleeping sickness is a unique sleep 
disorder that is caused by certain insect-borne parasites 
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Sleep disorders are typically diagnosed through sleep studies that utilize either 
PSG, or another method of measuring sleep and wakefulness called actigraphy.20 
Actigraphy is a non-invasive method of measuring daily activity and requires patients to 
wear a wrist-watch-like unit that contains an actimetry sensor. This actimetry sensor 
records movement as well as light exposure. The clear advantage of actigraphy over 
polysomnography is that it is much less invasive than PSG, where PSG not only requires 
placement of several electrodes and electrical leads on the patient, but also requires them 
to arrive in the early evening to a sleep lab or hospital and sleep in that location for the 
night. This typically presents challenges in children with and without autism that are 
subject to the “first-night effect”, where the first night’s sleep quality is markedly 
decreased as a result of having to sleep in an unfamiliar environment and while wearing 
the polysomnographic recording apparatus. 20,23 However, most patients habituate to the 
sleep lab and PSG apparatus by the second night. The disadvantage of actigraphy is that 
the single unit worn on a patient’s wrist cannot record as much data as is obtained in PSG 
studies. Sleep behaviors and parameters that are typically measured during PSG that 
characterize a person’s sleep include: sleep efficiency (SE), sleep duration / total sleep 
time (SD/TST), sleep onset latency (SOL), and wake after sleep onset (WASO). SE is the 
relationship between time spent asleep versus time spent in bed, sleep onset latency refers 
to the delay between full wakefulness and stage 1 sleep, and WASO indicates frequency 





Prevalence and Impact of SD in TD 
Current literature suggests the prevalence of SD in neurotypical children to be 
anywhere from 3.7% to 26%, depending on what sleep disorders are examined as well as 
what population is studied.43, 44, 45 Though there may be some disparity in the exact 
incidence of sleep disorders in a pediatric population, there is agreement on the effects of 
these sleep disorders. For example, delayed sleep phase disorder (DSPD) is one of the 
most prevalent disorders in young adults, occurring in 7-16% of patients.20, 62 DSPD is 
the chronic dysregulation of circadian rhythm, resulting in altered sleep timing and 
difficulty waking up. DSPD and other sleep disorders are associated not only with 
narcolepsy, but also several other medical and psychiatric diseases.  
The relationship of sleep disorders and other comorbid medical/psychiatric 
conditions is not yet fully understood, but what is certain is the increased association 
between the two represents a challenge to those with concurrent sleep and other 
disorders. In pediatric populations, disruption of normal sleep is associated with 
behavioral problems and impaired cognitive functioning. 103, 105 In otherwise healthy 
adults, sleep disruption is associated with somatic pain, emotional stress, mood disorders, 
and cognitive, and memory deficits.104 Furthermore, chronic sleep-disruption has been 
implicated in increased incidence of hypertension, cardiovascular disease, weight-related 







Literature Search Strategy 
 A systematic review of studies discussing sleep disorders within a context of ASD 
was performed. Three electronic databases: PubMed and Embase, Cochrane Reviews 
Library, were searched from database inception to January 2019. Appropriate MeSH 
terms, search terms, and Boolean operators were used to identify all studies: “autism”, 
“autistic”, “autism spectrum disorder”, or “ASD” and “sleep” or “sleep disorder”. 
Reference lists of all articles found were searched in order to identify potentially relevant 
studies. The search from Pubmed as of January 2019 yielded 1,091 results, 2419 results 
from Embase, and 124 results from Cochrane Reviews Library. After removal of 
duplicate results, 1130 studies remained. A search query on ClinicalTrials.gov was also 
performed in the same manner as the literature search, which showed 55 results. Of the 
55, 15 were selected for inclusion in this review after screening for study status, and 
relevance to sleep and autism. 
 
Selection criteria 
Studies eligible for this review were those which specifically included patients 
with ASD, Asperger's syndrome, and other neurodevelopmental disorders associated with 
autism. All studies selected were written in English, or were translated for full-text 
availability in English. If more than one article had been published from the same center 
with the same dataset, the study with the most complete and up-to-date dataset was used. 
 
25 
Single-case studies, case series were excluded. After title/abstract screening for relevance 
to sleep and autism in both pediatric and adult populations, 91 articles remained. Full text 
eligibility led to the inclusion of 71 studies. Clinical trials were selected for active status 
regardless of recruitment status, and with no other restrictions. 
 




SLEEP IN AUTISM SPECTRUM DISORDERS 
Overview 
 Autism research has largely focused on the assessment and understanding of the 
many clinical characteristics observed in the disorder. This includes features of speech, 
social, and behavioral patterns, cognitive development, sensory information processing, 
and the relation of these aspects to the gross and microscopic anatomy, neurochemistry, 
architecture of the brain, and potential genetic contributions. 11 Much has been learned in 
the past 40 years, but one area of inquiry that remains incompletely explored is the 
interplay of other organ systems and their impact on the pathology of sleep disorders in 
ASD.  
 
Prevalence and Impact of SD in individuals with ASD 
Sleep problems are highly prevalent in children with ASD and in epidemiological 
studies in these children, present as one of the most common concurrent clinical 
disorders. 11 There is no agreement on the exact prevalence of SD in children with ASD, 
and the reported rates have ranged from 40% to 80%.11,47 However, when compared to 
TD children in which prevalence rates range from 4% to 30%, there is consensus in the 
fact that children on the spectrum experience more frequent sleep troubles.43, 44, 45 Recent 
reports indicate that there has been a significant increase in the number of office visits for 
sleep disorders and sleep related problems as well as in the an increase in prescriptions 
for sleep medications accompanying these visits.103 However, there seems to an alarming 
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lack of awareness of SD among pediatric and adult populations, and multiple reports 
authored by the CDC share the conclusion that greater awareness is needed.103,104,105 The 
most commonly reported sleep problems are delayed sleep onset, impaired sleep 
maintenance, and decreased sleep duration.105 Children with ASD also experience other 
types of sleep issues such as parasomnias, breathing disorders, sleep-related movement 
disorders, and circadian rhythm disorders. Children with ASD experience longer periods 
of waking after sleep onset, up to 2 to 3 hours per night.11,62 While awake at night, the 
most commonly observed behaviors are laughing, talking, or getting up and playing with 
toys/objects in the room, which is atypical compared to TD controls or children with 
other developmental disabilities.11 Disordered sleep affects daytime health and may cause 
behavioral disruptions as well as neurocognitive dysfunction. In ASD children, sleep 
disruption may cause daytime sleepiness and has been shown to exacerbate aggression, 
hyperactivity, or inattention.33 SD thus may impair normal daytime functioning, inhibit 
developmental progress, and lessen quality of life for both the child and their family.  
Current research suggests that children with ASD seem to experience greater 
subjective sleep troubles such as bedtime resistance, sleep anxiety, sleep-disordered 
breathing and parasomnias, as well as longer sleep onset latency (SOL) and increased 
daytime sleepiness.48,62,65 In examining objective data, children also showed significantly 
lower total sleep time (TST), and worse sleep efficiency (SE) compared with typically 
developing children.48 One study concluded that ASD children are at a high risk for 
developing sleep problems, and that these are associated with daytime behavior 
disturbances. The most common sleep problems reported in these children are sleep-wake 
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transition disorders, followed by disorder of initiation, and maintenance of sleep.49 
However, it is possible that clinicians under-report sleep problems in children with ASD 
and ADHD, with one study showing significant variation among 12 medical centers in 
the United States.38  
As previously discussed, sleep disorders resulting in sleep disturbances have 
several negative effects in TD children. In children with ASD, abnormal sleep patterns 
are moderately associated with increased autistic behavior and impaired social 
interaction.11,49,64 This is supported by evidence indicating that worsening autistic 
symptoms are significantly associated with lower TST during the weekday. Moreover, 
autistic symptoms remained as an independent predictor of decreased TST when 
controlled for comorbid psychiatric symptoms.50 Concomitant sleep disorders have been 
linked to worsening of autistic traits as well, as evidenced by a study that concluded poor 
sleep was associated with higher rates of stereotyped behaviors, negative affect, which is 
feelings of distress and negative emotions such as anger, fear, and nervousness, and a 
collection of overall challenging behaviors. This paper also suggested interventions that 
aim to improve sleep patterns may have essential positive downstream effects on 
problematic behaviors and developmental outcomes for children on the spectrum, as well 
as quality of life improvement for ASD children and their parents.39  
The above findings have been corroborated by studies conducted on pediatric 
participants, including a predictive model developed by Shui et al. which indicates that, 
in children with ASD, sleep problems independently predicted aggressive behaviors.51 
Another study showed that higher scores on the Aberrant Behavior Checklist-Community 
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(ABC-C), a standardized assessment which measures irritability, stereotypy, and 
hyperactivity, were significantly associated with fewer minutes slept at night during the 
study period.52 One limitation of this study is related to the fact that the participants were 
psychiatrically hospitalized and presented with other medical and psychiatric 
comorbidities. The authors acknowledge this may have impacted on whether a 
connection between sleep deprivation and aggression/violence may be conclusively 
drawn in pediatric patients with ASD.52 In summary, both pediatric and adults with ASD 
present with numerous sleep difficulties, and the literature confirms the fact that sleep 
disorders can have a compounding effect on exacerbating certain autistic traits. The 
prevalence of these sleep-related issues in ASD is significantly higher when compared to 
TD individuals, and furthermore it is not yet fully understood whether these disorders are 
causal or a result of other comorbidities.  
 
Sleep characteristics of children with ASD 
Sleep disorders in ASD children are often comorbid with other psychiatric, 
medical, and neurological conditions. This is different from sleep disorders and insomnia 
as seen in the TD pediatric population, which typically have a behavioral component in 
their etiology.20,103 Individuals with ASD present with sleep difficulties including low 
sleep efficiency, prolonged sleep latency and an increase in number/length of night 
awakenings, increased daily sedentary behavior, increased nocturnal activity, and 
disorders of sleep architecture.77 Notably, there is additional evidence that children with 
ASD who regress exhibit longer sleep onset latency (SOL), increased wake after sleep 
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onset (WASO) frequency, and increased bedtime resistance compared to their typically 
developing peers.14 The causes of these discrepancies are still not fully understood, but 
several studies have elucidated physiological differences between patients with ASD and 
TD controls.  
One notable discrepancy that should be discussed is differing accounts of sleep 
parameters and sleep behaviors in the literature. A large meta-analysis of sleep literature 
in children with ASD reveals that children on the spectrum and TD controls did not have 
significant differences in sleep duration based on parental/caregiver reports. 53 However, 
when examining PSG measures, children with ASD exhibited significant differences 
when compared to their peers.53 Further, variability in objective PSG measures has been 
reported in studies with children on the spectrum.54 This may be owed to the fact that 
subjects with ASD who participate in PSG studies take longer to acclimate to the foreign 
environment in which sleep studies take place. Although subjects eventually acclimatized 
to the new environments, this may explain some of the variability of PSG within 
individual ASD subjects and between ASD subjects and TD controls.55 This does not 
suggest however that studies should look toward using different methods of measuring of 
sleep behavior, i.e. using actigraphy. Actigraphy is limited to collecting only activity data 
during the day and total sleep time (TST). Although it is easier to achieve compliance, 
were researchers to switch to actigraphy studies, the results might reflect less robust data. 
Current literature is moving toward the recommendation of multiple-night sleep studies 
rather than single-night studies that can produce data that reflects the true 
electrophysiology of individuals with ASD.
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Heart rate variance 
In PSG studies, cardiac activity has been shown to be altered for individuals with 
ASD. Studies examining variability in heart rate variability (HRV) have shown that when 
compared to TD adults, ASD adults exhibited HRV that was significantly different 
during an awake state in the morning following a regular night of sleep, which is 
indicative of lower parasympathetic activity.56 This is supported by the finding that 
children with ASD have higher sympathetic and lower parasympathetic activity during 
slow-wave sleep and REM sleep than TD children. Heart rate (HR) data was initially 
reflective of normal HR changes that occur during sleep - namely increased HR during 
NREM sleep and increased HR during REM sleep. In children with autism however, HR 
was significantly elevated in stages 2, 3, and REM sleep when compared to TD 
controls.56, 57 These studies implicate the vagus nerve, which is the tenth cranial nerve and 
which is responsible for parasympathetic regulation of the heart, lungs, and digestive 
tract. These findings suggest altered vagal influence in ASD, resulting in higher 
sympathetic activation, and lower parasympathetic activation during sleep.57 Taken 
together, studies examining cardiac activity in individuals with ASD suggests an altered 
neurology resulting in atypical autonomic nervous system control. 
 
EEG differences 
Numerous published works have examined characteristics of EEGs of children 
with ASD while they are asleep. In children with ASD that did not have any pre-existing 
sleep disorders or any other psychiatric or medical diagnoses besides ASD, it has been 
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shown that during NREM sleep in children with ASD, abnormal slow wave readings in 
EEGs (which are generated by thalamo-cortical loop neurons) could reflect atypical 
cortical maturation patterns previously shown in ASD.58 Children with ASD have also 
been shown to demonstrate shorter duration of REM sleep and altered REM sleep 
architecture that has been confirmed via EEG recordings.14, 59 Such studies that evaluate 
EEG differences demonstrate agreement in the presence of abnormal EEG measurements 
as well. EEG abnormalities are reported in roughly 40% of ASD participants and are 
notably epileptoid, or resembling epilepsy. It should be noted that in these papers, 
approximately a fifth of study participants with ASD also had comorbid epilepsy.58,59 
Atypical EEG readings during sleep were correlated with increased autism severity, 
aggression, destructive behavior, stereotyped behaviors, self-injurious behaviors, 
communication deficits, and intellectual disability.59 The relationship between these 
epileptiform EEG recordings and atypical sleep patterns remains uncertain. However, the 
simultaneous observation of epileptiform or epileptic EEG measurements during sleep 
suggests a neuronal dysfunction within areas of the brain that are important in sleep. This 
may be indicative of an underlying pathology common to individuals with ASD.14 The 
authors of this study also suggest that chronic seizures experienced by participants may 
be caused by the aforementioned underlying pathophysiological mechanism, and may 





ETIOLOGY OF SLEEP DISORDERS IN ASD 
The bidirectional model 
Literature exploring the etiology and underlying mechanisms of sleep disorders in 
autism are not yet comprehensive, but one predominant framework has emerged in recent 
years: the bi-directional model. ASD is a complex and multifactorial disorder. The causes 
of sleep disorders and sleep problems in children with ASD are equally complex, but 
these two disorders are not mutually exclusive. Certain behavioral factors such as 
atypical bedtime rituals may disrupt sleep, especially sleep onset latency (SOL).54 There 
is also growing evidence in the involvement of dysregulated circadian rhythms 
contributing to sleep disorders in ASD, and of these circadian rhythm disorders, ones that 
are endocrine and genetic in origin seem to contribute the most towards neurochemical 
alterations and metabolic dysfunction.42, 59, 60, 61 However, this raises the question of what 
role, if any, other medical, neurological, and psychiatric conditions play in the etiology of 
sleep disorders. It has been shown that various comorbidities either exacerbate autistic 
traits and may even be implicated in regression.12, 62 The bidirectional model offers an 






Figure 3: The bidirectional model of sleep problems in ASD. Biological and genetic 
abnormalities related to melatonin and GABA may lead to sleep problems and disrupted 
sleep architecture in ASD individuals. Sleep troubles are a feature of the ASD phenotype 
and also represent concomitant psychiatric conditions observed in ASD. RRBs = 
Restricted interests and repetitive behaviors; MD = Mood Disorders. Taken from 
(Limoges et. al., 2013).  
 
The bidirectional model describes the intersectionality of concomitant 
pathophysiological, behavioral, communicative, medical, neurological, and psychiatric 
comorbidities. To better understand each component, it is best to consider each facet of 




1. Genetic, neurochemical, and environmental abnormalities may lead to the sleep 
problems in ASD, and in turn SD may influence the aforementioned 
abnormalities. 
2. Clinical features of autism such as stereotypic and ritualistic behavior contribute 
to SD and sleep problems reciprocally may worsen autistic traits. 
3. Sleep problems are related to, if not caused by psychiatric comorbidities such as 
anxiety, mood disorders, and ADHD which further exacerbate SD. 
 
These relationships are not mutually exclusive and it is possible that there is an 
interaction between causative aspects. Understanding the directionality of these 
underlying mechanisms becomes further complicated when taking into consideration the 
impact of pharmacological treatment and its potential side effects.  
 There is not complete consensus relative to the validity of this model. A handful 
of studies have suggested that while this model is useful for thinking about sleep 
disorders in autism, other authors have presented evidence that disagrees with this model. 
Data suggest that SD and ASD may co-occur, but there is little to no causal relationship 
between the two.63, 64 New data from a study published in January 2018 by Verhoeff et. 
al., is in agreement with this viewpoint. Verhoeff et al. sought to better understand the 
temporal nature of SD in ASD, by determining whether sleep issues occur before and/or 
worsen autistic symptoms, or whether sleep issues occur after (i.e. as a result of) ASD 
diagnosis. This study did not agree with the previously determined association between 
worsening autistic traits and sleep problems. Additionally, from their study cohort of 
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5151 Dutch children that included 81 children diagnosed with ASD, the authors 
ultimately concluded that SD and ASD are not bidirectionally associated.64 Verhoeff et. 
al., go on to suggest that SD are part of the construct of ASD. This is disagreement must 
be acknowledged, and more research that studies this etiological mechanism is required. 
At the time of writing, there is no literature that either refutes or supports this claim. 
 
Genetic linkages 
Current research suggests that genetic mutations that have been connected to 
autism also influence multiple aspects of abnormal sleep, from metabolic deficiencies to 
circadian rhythm.42 One of most well-studied aspects of SD that plays a role in ASD is 
the importance of melatonin. Previous literature has confirmed that children with ASD 
generally have lower melatonin levels. Specifically, lower levels of both daytime and 
nocturnal serum melatonin as well as lower levels of the primary metabolite 6-
sulfatoxymelatonin (6-SM) have been observed.65, 66, 67, 68 It should come as no surprise 
then this has been a growing area of research in the last 10+ years.  
To understand the genetics of melatonin production and its downstream effects, 
we should examine the biochemical and genetic factors in melatonin synthesis and 
metabolism. Two melatonin pathways genes that are of interest are genes that encode 
acetylserotonin O-methyltransferase (ASMT) and cytochrome P450 1A2 (CYP1A2). 
Melatonin synthesis involves a series of enzymatic reactions requiring ASMT enzyme in 
order to convert serotonin to melatonin.67 Melatonin metabolism is primarily carried out 
by the liver enzyme, CYP1A2.69 There is also literature suggesting a potential 
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relationship between predictive slow-metabolizing alleles in CYP1A2 and increased risk 
of comorbid sleep problems in ASD.70  
 Veatch et. al., use this context to examine genetic linkages of SD in children with 
ASD. Melatonin is an endogenous hormone released by the pineal gland that functions to 
regulate sleep-wake cycles. Melatonin also reduces oxidative stress, which is shown to be 
harmful to the central nervous system.67 This protective effect becomes important in 
studies that discuss melatonin deficiency in ASD which have an underlying mechanism 
that is genetic in nature. Some authors suggest that the neuroprotective and sleep 
homeostatic roles of melatonin could decrease the risk of neurodevelopmental disorders 
such as ASD.63 However, Vetach et. al. have approached this question in a different way. 
They have shown that children with autism and comorbid SD such as increased SOL 
carry greater dysfunctional variant genes in the melatonin metabolism pathway, namely 
those for ASMT and CYP1A2.71 These findings were expanded upon in another study 
that examined levels of melatonin metabolite. In this study, low parental melatonin levels 
were investigated as being a potential contributors to ASD.72 Investigators measured 6-
sulfatoxymelatonin in urine of 60 mothers of children with ASD and age-matched 
controls, and found significantly lower 6-SM excretion in mothers of ASD children.59 
Parental melatonin levels are thought to act in two independent mechanisms: directly by 
causing atypical development of children’s brains and indirectly by increasing 
susceptibility to DNA damage in parental germ cells and environmental risk factors. The 
data presented in this study suggests that if children with ASD also had lower levels of 
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melatonin, this deficiency would explain the greater impact of SD on brain 
development.59  
 Although the genetics behind melatonin levels and melatonin pathways have been 
well studied, there is sparse literature that examines the effect of other 
hormones/neurotransmitters in SD, such as serotonin, histamine, GABA, or dopamine in 
the context of SD in ASD. However, recent literature in animal models point toward a 
multi-factorial component of SD etiology. Neurexins are cell adhesion molecules 
involved in the formation of neurons and synaptic transmission. Mutations in neurexin-
encoding genes are associated with both ASD and sleep disorders.73 There is limited work 
that examines SD and mutations in neurexin genes in humans, but one study in the 
Drosophila found that neurexin regulates nighttime sleep by mediating the synaptic 
transmission of certain types of neurons.73 Future studies in humans should examine 
mutations in neurexin genes and consider whether individuals with ASD exhibit 
abnormal synaptic transmission that can contribute to sleep disorders.  
Another potential avenue of genetic research involves Narcolepsy type 1, a rare 
chronic neurologic disorder resulting in excessive daytime sleepiness. Type 1 narcolepsy 
is due to the deterioration of hypothalamic orexin-containing neurons. In children with 
ASD and type 1 narcolepsy, loss of neuronal density is due to presumed autoimmune 
mechanisms triggered by environmental factors in genetically predisposed individuals.51 
This suggests that while genetic etiologies may be a factor in sleep problems in ASD, 
environmental factors may also play a role. However, there is currently no literature that 
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has specifically examined the impact of environmental factors on sleep issues in subjects 
with ASD. 
 
Medical comorbidities  
Another aspect of the bidirectional model is that of the medical, psychiatric, and 
neurological comorbidities that may contribute to SD. One study suggests that anxiety 
and SD are possibly early predictors of ASD in young children. This study supports the 
interrelation of sleep troubles, anxiety and autistic traits and also indicates all three may 
present concurrently in young children with ASD.63, 66 A recent study confirmed 
associations between comorbidities that have been previously observed, such as sleep 
disorders and anxiety symptoms in older children.62, 66 Other associations found that had 
not been previously shown in published literature were constipation with sleep disorders, 
and irregular eating habits with SD (in younger children only). Intellectual disability has 
also been associated with sleep disturbance in children with ASD.66 This may suggest a 
larger picture of treating concomitant disorders in ASD as a potential area of future 
research.67 This is further explored by Youssef et. al., who demonstrated anxiety and 
sleep troubles may be an early predictor of autism in young children, and vice versa, 
where presence of autistic traits early in development may also contribute to and/or 
exacerbate later anxiety disorders.68 Anxiety seems to be the predominant area of study 
that contributes to SD, but more work in other comorbidities is needed. 
Medical comorbidities that may influence SD include GI and ENT conditions. 
One review reported significant differences in sleep disturbance rates between ASD 
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subjects and TD controls that exhibited GI symptoms. Sleep disturbances were present in 
over 50% of children with ASD who had concomitant GI symptoms, compared to 7% of 
age-matched TD controls exhibiting similar GI symptoms.74 Symptoms such as 
abdominal pain and irritable bowel syndrome may negatively impact sleep by making it 
more difficult for children with ASD to relax and transition into stage 1 sleep, thus 
delaying sleep onset (SOL). Abdominal discomfort may also be so intolerable that it 
leads to increased awakenings, which would ultimately affect total sleep time.3, 74 Current 
literature on the mechanisms by which GI issues influence sleep parameters and sleep 
architecture is limited. Studies which quantify sleep disturbances that may have an 
underlying gastrointestinal etiology in ASD patients are also needed. 
Otolaryngologic comorbidities such as enlarged adenoids, sinusitis, infection of 
the middle ear (otitis media), and sleep apnea might also have unique influences on sleep 
in ASD children. These conditions, such as sinusitis, with its associated symptoms of 
headache, runny nose, and nasal congestion, may negatively influence a child’s breathing 
patterns during sleep.62 These is little published literature that delineates a relationship 
between these ENT issues and SD, and it is still unclear whether SD are worsened by 
conditions such as sleep apnea and enlarged adenoids, or are due to these comorbidities. 
Other medical problems that may influence sleep are urinary incontinence and lower 
urinary tract symptoms. Such urological problems have been implicated in nocturnal 
enuresis (bedwetting) and have been reported to negatively impact sleep.75, 76 However, 
literature on this topic is sparse and the influence of urological comorbidities on sleep is a 





Knowing that individuals with ASD may demonstrate hypersensitivity to external 
stimuli, it follows that this hypersensitivity plays a role in SD in children with ASD. 
Indeed, recent literature has begun to implicate the role of sensory processing disorders in 
children on the spectrum who may have difficulties with hyperarousal that can be traced 
to impaired sensorimotor inhibition.77 Further still, new data show that hypersensitivity 
toward physical touch interferes with regular sleep onset in a cohort of children with 
ASD and age-matched controls.78 This is a new area of research, and it remains to be seen 
how this neurologically-related mechanism of sleep disturbance fits into current models 
of SD etiology in children diagnosed with ASD.  
The etiology of SD in ASD is beginning to be better understood, and various medical, 
behavioral, and genetic contributors have been studied. However, the question still 
remains whether mechanisms fully these support the bidirectional model of SD in ASD. 
Taking the collective literature as whole it seems to tentatively fit this model, but as 




THERAPEUTIC INTERVENTIONS FOR SLEEP PROBLEMS IN ASD 
Medical interventions 
A challenge clinicians face in treating SD in ASD is determining whether a sleep 
problem is secondary to medical, neurologic, or psychiatric comorbidities the child 
experiences. If sleep issues arise only as a result of those comorbidities, then treatment of 
those conditions should lead to resolution of the sleep problems as well. Current clinical 
practice is to rule out medical explanations for SD in ASD before turning toward 
behavioral or pharmacological intervention.20 Treatment of GI problems may lead to 
sleep improvements, since difficulty transitioning to sleep and increased nighttime 
awakenings are associated with GI issues such as abdominal discomfort and 
gastroesophageal reflux disease (GERD).19 Yet, there is no current literature which 
confirms that medical treatment of GI problems is what leads to better sleep outcomes. 
There are also limited published studies that discuss treatment of ENT issues leading to 
improvements in sleep. However, one study demonstrates improvement in behavior and 
sleep after treating ENT problems. One such article discussed children with ASD and 
concomitant obstructive sleep apnea (OSA). Surgical intervention was employed to treat 
OSA, and following removal of the adenoids and tonsils (also known as 
adenotonsillectomy, or AT) in these children with ASD, the authors observed 
improvements in autistic symptoms and sleep patterns.21  
It appears that if SD are identified to be secondary to medical comorbidities, 
treatment of these conditions likely improves the symptoms of SD. However, further 
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work is required to determine what kinds of interventions are most efficacious and best 
suited to treat these medical comorbidities, and whether invasive procedures such as AT 
are the safest interventions for use in pediatric populations. 
 
Behavioral interventions 
Behavioral interventions that aim to improve sleep and sleep habits are generally 
the first prescribed treatments for SD in ASD. Current guideless have not conclusively 
recommended the use of psychopharmacological treatments in autism, but these are still 
frequently prescribed.20, 27, 91 Melatonin has the largest body of evidence supporting its 
use, but other drug classes such as antipsychotics, antidepressants, and alpha agonists are 
also generally used. Behavioral intervention is shown to moderately efficacious and may 
also lead to non-sleep related improvements.79 Other interventions that aim to establish 
sleep hygiene and bedtime routines are also moderately efficacious.80, 81 These 
interventions employ similar techniques used with TD children such as reducing 
electronic device usage close to bedtime, and creating routines for children which allow 
them to associate certain actions such as brushing teeth and putting away toys with going 
to sleep. Whether improvements in SD are causal of autistic symptoms improvement 
remains to seen, and it may be difficult to elucidate the relationship between these two 





Behavioral interventions that are implemented during the day show promising 
improvements in treating SD. In preschoolers with ASD, physical activity during the 
morning and afternoon is shown to advance median sleep onset time, leading to increased 
total sleep time (TST).82 Further studies that employ physical activity interventions such 
as basketball skills training are also shown to be effective in improving SE, SOL, and 
TST.83 Tse et. al., also noted that in a cohort of 40 children with autism, the basketball 
skills intervention was associated with improvement of autistic traits, specifically, 
inhibition control. The authors suggest that physical activity alters melatonin levels.83 It 
has been previously demonstrated that cardiovascular activity during the day was 
associated with significantly increased blood melatonin levels, but the biochemical 
processes that facilitate this increase are not known.84 Tse et. al. found that salivary 
melatonin levels were increased during and after physical activity, and hypothesized that 
this was responsible for increased blood melatonin levels, which were later associated 
with improved sleep outcomes. The authors also note that exercise has other benefits such 
as reducing anxiety and increasing brain-derived neurotrophic factor.83 Still, the specific 
processes underlying exercise-related improvements in sleep are unclear.    
One trend in the literature that involves physical activity interventions is that data 
are typically gathered through actigraphy. As previously discussed, actigraphy is more 
feasible and often more cost-effective than PSG, but future work should incorporate PSG 
measurements to confirm and better reveal the mechanism behind physical activity 
interventions. Another potential study modification would be to examine the effect of 
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these physical activity interventions on blood and salivary melatonin levels, in order to 
further elucidate the mechanism of behavioral treatments.84 
 
Bedtime Fading 
Bedtime Fading with Response Cost (BFRC) is a recent invention shown to be 
effective in improving SOL, bedtime resistance, and disruptive sleep-related behaviors. 
BFRC is the combination of bedtime fading and an additional modification of 
intervention protocol. Bedtime fading alone is a method of sleep training where the child 
is allowed to sleep late for a handful of nights, and over the course of successive nights, 
the bed time is moved to earlier times in the evening. Bedtime fading is shown to be 
efficacious since the time at which caregivers put the child to bed is adaptive, so that the 
child progressively goes to bed when they are tired.85,86 Response cost is a modification 
of this procedure where if a child does not fall asleep within 45 minutes of his/her 
bedtime, the child is taken out of bed and allowed to engage in activities not related to 
bedtime, such as playing with toys and watching TV. The benefit of response cost 
suggested by investigators and practitioners is that it allows for more rapid bedtime 
fading, which in turn reinforces the value of sleep.85 Studies utilizing this treatment as 







A meta-analysis published in 2019 examined five randomized, double-blind, 
placebo-controlled crossover trials that utilized exogenous melatonin supplementation in 
ASD. This study found significant improvements and large effect sizes in increasing TST 
and improving SOL compared to both baseline and placebo.87, 88 Another study found 
similar improvements when melatonin was combined with a behavioral intervention 
focused on improving sleep.88, 91 Investigators employed both CBT for improving sleep 
habits/sleep anxiety and found improved outcomes from melatonin supplementation 
alone.89 Melatonin is generally well tolerated. Adverse effects experienced in children on 
the spectrum taking melatonin are similar to those seen in TD controls, including daytime 
sleepiness and abnormal dreams.88, 90   
There is considerable evidence that melatonin is effective in the treatment of at 
least some aspects of these sleep disorders. Further studies should evaluate feasibility as 
well as validate efficacy of combining melatonin and other behavioral interventions. 
 
Other sleep medications 
Major drug classes such as alpha-agonists, anticonvulsants, antidepressants, 
atypical antipsychotics, and benzodiazepines have been used in treating SD in ASD.91 
The challenge in prescribing these “off-label” is that these medications are frequently 
associated with negative side effects. Such adverse effects including worsening of autistic 
traits, daytime sleepiness, and cognitive or memory impairment.31, 88, 91The 
pharmacodynamics of these medications are poorly understood in ASD populations, as 
polypharmacy often complicates and hinders direct comparison of mechanisms of action 
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and outcomes.31, 91 Current practice is to individualize these treatments to patients with 
ASD and to closely monitor for any adverse reactions.20 Clonidine, an alpha-agonist, and 
trazodone, an antidepressant, are shown to improve sleep onset, and are both weakly 
associated with other improvements in sleep parameters such as decreased wake after 
sleep onset.91, 92 Clonidine appears to have acceptable tolerability, and the only 
demonstrated adverse effect related to sleep is decreased REM sleep.93 Antidepressants 
such as trazodone however are associated with daytime sleepiness as well as decreased 
REM sleep.91 Such medications are still considered useful to ameliorate sleep problems 
because they also treat concomitant depression in individuals with ASD.94 Whether these 
medications have long-term effects on sleep architecture in children on the spectrum is 
unclear, and further research is needed to better understand mechanisms of action and the 
pharmacodynamics of these drug classes in individuals with autism. 
Other pharmacologic interventions include transdermal nicotine, which not only 
was shown to improve aggression, but also improve subjective sleep ratings.33 
Additionally, cannabidiol (CBD) has been very weakly associated with improvement in 
sleep issues.96 CBD remains illegal under federal law but has been approved for medical 
and recreational use in a handful of states.95 The only published study using CBD in 
treating SD in children on the spectrum was unable to conclude CBD oil is effective, 
since the authors observed improvement of sleep in some subjects, but also saw worse 
sleep outcomes in other subjects within the same treatment arm.96 Mechanism of action, 
tolerability, and adverse effects are not well studied for CBD to treat SD in ASD. This 
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may be a potential area of future work, but faces considerable ethical and legal and 
challenges.  
Current standard clinical practice in treating sleep in ASD is to attempt behavioral 
intervention before moving to pharmacological intervention.20, 97, 98 However, as some 
literature suggest, a combination of these two may have an additive effect in improving 
sleep outcomes.89 Other combinations of daytime or nighttime interventions and 
compounds other than melatonin should be examined for efficacy and tolerability, and 
ideally these trials would utilize robust methodologies in body function measurement 
such as PSG. 
 
Complementary supplementation 
Exogenous melatonin is frequently used in pharmacological supplementation, but 
other compounds have been studied as well. L-carnosine has been suggested as 
potentially effective in improving sleep disturbances in an ASD cohort, but specific 
mechanisms remain unclear.99, 102 Carnosine is a dipeptide molecule and is composed of 
the amino acids beta-alanine and histidine. Previous studies strongly support the idea that 
this peptide acts as an antioxidant and neuroprotective agent.99 Additionally, clinical trial 
data show that patients with ASD have lower circulating carnosine than age-matched 
controls.100, 101 Results from these recent randomized, controlled clinical trials show 
improvement in not just sleep outcomes, but also behavioral and speech deficits.35The 
nature of this benefit remains unclear, because as discussed previously, sleep has been 
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There are a myriad of non-pharmacological complementary treatments used for 
SD in children with ASD. These may include rearranging sleep environments so that 
children sleep close to walls and are able to experience tactile stimulation by rubbing 
against walls, white noise machines, and weighted blankets.102, 103 Taken together, it 
would appear that these treatments involve sensory stimulation, either tactile or auditory, 
which mediates improved sleep outcomes. There is little literature supporting the use of 
these treatments due to unproven efficacy, and a study in 2014 was unable to show that 
weighted blankets helped improve sleep in children with ASD.6 However, this same 
study noted that children tolerated the blankets well and favored them compared to 
controls.6 This may suggest that complementary treatments might have a perceived 
efficacy which facilitates improved sleep, which is akin to a placebo effect.6, 102 Still, 
further work is needed to understand the role of sensory stimulation on sleep, especially 





Ongoing research in SD and autism aims to better delineate etiology and 
interactions. Ongoing clinical trials are shown below: 
Table 1: Registered clinical trials to treat Sleep and ASD that are active or complete 
but do not yet have published data  
Status Study Title Intervention 





Examining the Association Between Physical Activity and 




Sleep, Autonomic Nervous System and Cardiorespiratory 




Completed Targeting Sleep in Kids With Autism Spectrum Disorder Behavioral: Cognitive Behavioral Therapy 
Not yet 
recruiting 
Internet-delivered Cognitive Behaviour Therapy for Sleep 





Completed Iron Treatment of Sleep Disorders in Children With Autism Spectrum Disorder Drug: Ferrous sulfate 
Recruiting Pilot Study of Sleep Therapy and Biomarkers in Children With Autism Spectrum Disorders 
Drug: Melatonin and 
Donepezil 
Completed Telephone Care Management to Address Sleep Problems in Young Children With Autism 
Behavioral: Telephone 
Care Management 
Completed Examining the Efficacy of Mattress Technology in Improving the Sleep Quality of Children With ASD 
Device: Sound to Sleep 
System 
Completed 
The Effects of a Clean Room Sleeping Environment on 





A SMART Design to Improve Sleep Disturbance in 







Completed Essential Oils for Enhancing QOL in ASD Biological: Essential Oil Mixture A/B 
Completed A Bicycle Training Intervention Behavioral: Bicycle Training Intervention 
Completed 
Assessment of the Pharmacokinetics of Circadin® in 
Children With Neurodevelopmental Disorders and Sleep 
Disturbances 
Drug: Circadin 2/10 mg 








Drug interventions: 4 





The heterogeneity of ongoing clinical trials reflects the multidimensional approach that 
researchers and clinicians are utilizing to treat SD in ASD. As data becomes available 
from these studies, further work will be done to analyze and interpret these findings in the 





 Much has been learned in the past 10 years of sleep research with individuals on 
the Autism Spectrum. Much of the research has been focused on younger patients, but 
studies involving adolescents and adults reveal similar findings in pathophysiology, 
etiology, and treatment outcomes. There is still much to be uncovered regarding the 
underlying mechanisms of sleep pathology on the molecular, cellular, organ, and systems 
levels. However, the demonstrated efficacy and breadth of potential therapeutic 
interventions is encouraging. Future studies should consider incorporating a 
polysomnographic component in study design, in order to strengthen and provide more 
robust data. Management of sleep disorders in autism is generally practiced on a case by 
case basis, as the disorder is very heterogeneous, and it is likely that no two patients share 
a common etiology of sleep issues or respond in the same way to therapeutic 
interventions. Summarily, the increasing awareness, interest, and innovation in sleep 
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